Interferon-α (IFN-α) is an antineoplastic agent in the treatment of several solid and hematological malignancies that exerts strong immune and autoimmune stimulating activity.
Introduction
IFN-α is a well-known antineoplastic drug that exhibits both antitumoral and immune stimulating activities (1, 2) . Among IFNs, IFN-α2 has been most broadly clinically evaluated and established as a treatment in a multitude of malignancies, including several hematological malignancies and solid tumors (3) (4) (5) . Direct effects on tumor cells include inhibition of growth-promoting cytokines, induction of apoptosis, inhibition of cell proliferation and enhancement of tumor cell immunogenicity. Immune stimulating actions of IFN-α are promotion of dendritic cell (DC) maturation, facilitation of T cell activation and stimulation of natural killer (NK) cell activity. Therapeutically applied, IFN-α also increases the risk for development of autoimmune symptoms as frequently observed in tumor patients upon prolonged treatment (6, 7) . Induction of autoimmunity by IFN-α has been ascribed to several mechanisms including amplification of T cell activation and improved survival of activated T cells (6, 7) . We recently observed that IFN-α also interferes with the induction of T cell tolerance by reversing human tolerogenic DC function (8) . However, the strong immune activating and autoimmune stimulating activity of IFN-α suggests that additional immune regulatory pathways could be affected.
CD4 + CD25 high Foxp3 + regulatory T cells (Treg) represent a specialized T cell subset skewed towards autoantigen recognition that plays a key role in the maintenance of self-tolerance by repressing immune responses against self antigens (9, 10) . Owing to their role in preserving immune privilege of self-antigens Treg confine the expansion and differentiation of T cells against tumor-associated self-antigens (11) . In line, elevated numbers of Treg in the tumor and tumor draining lymphoid tissues of cancer patients are associated with poor prognosis (12) and the efficiency of cancer vaccination could be improved by concomitant Treg depletion or blockade (13, 14) . As a consequence, emerging therapies for cancer aim at the on July 22, 2017. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 22, 2013; DOI: 10.1158/0008-5472. ablation or inhibition of CD4 + Foxp3 + Treg. Unfortunately, due to their phenotypic similarity current strategies such as anti-CD25 mAb used to deplete or inhibit Treg also target activated 
Materials and Methods

Analysis of intracellular signaling
STAT phosphorylation was measured in isolated Treg and Teff upon incubation with 10 4 U/mL IFN-α. Cells were fixed and permeabilized (BD Cytofix TM Buffer, BD PermBuffer III) and stained with anti-CD25-PE-Cy5, anti-STAT1-PE (pY701), anti-STAT3-PE (pY705), anti-STAT5-PE (pY694), anti STAT1-PE (BD Pharmingen), anti-STAT3-PE (all from BD Pharmingen, San Diego, CA), or anti-STAT5-PE (R&D Systems, Wiesbaden, Germany). ZAP-70 phosphorylation was determined in Treg pre-incubated with 10 4 U/mL IFN-α overnight and subsequent crosslinking by anti-CD3 (OKT-3) antibody. Cells were fixed with BD Cytofix TM Buffer and BD PermBuffer III, stained with anti-CD25-PE-Cy5/ZAP-70-PE (pY319, BD Pharmingen, San Diego, CA) and analyzed by flow cytometry (BD FACSCalibur). In some experiments, cAMP production was repressed in Tregs by pretreatment with the adenylate cyclase inhibitor MDL-12 (Calbiochem) (15) .
Suppressor assays
CD4 + CD25 -T cells (Teff) and CD4 + CD25 + (Treg) were isolated as described previously (8) .
For suppressor assays, 1x10 5 Teff and 1x10 5 Treg were co-cultured in X-VIVO20 and stimulated with 0.5 µg/mL anti-CD3 mAb (clone OKT-3) in the presence of irradiated allogeneic PBMC (90 Gy). Alternatively, T cells were stimulated with 0.5 µg/mL anti-CD3 mAb and 0.25 µg/mL anti-CD28 mAb. T cell proliferation was assessed at day 4 by [ 3 H]thymidine incorporation. Relative suppressor activity is presented as mean ± SD (proliferation of Teff + Treg normalized to proliferation of Teff=100 %).
For blocking of IFNAR2, Treg were pre-incubated with either 5 µg/mL mouse IgG2a isotype control (BD Pharmingen) or blocking anti-IFNAR-2 mAb (MMHAR-2) (PBL InterferonSource) overnight before subjection to suppressor assays. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 22, 2013; DOI: 10.1158/0008-5472. For inhibition of phosphodiesterases, the phosphodiesterase inhibitor 3-isobutyl-1-xanthine (IBMX, Sigma-Aldrich, Munich, Germany) (25 µM) or the PDE4-specific inhibitor rolipram (Cayman Chemicals, Ann Arbor, USA) (5µM), respectively, were added.
Assessment of cAMP production
Teff and Treg were incubated overnight with or without 10 4 U/mL IFN-α, subsequently stimulated with 0.5 µg/mL anti-CD3 mAb and 0.25 µg/mL anti-CD28 mAb for 6 hrs and cAMP was quantified using a cAMP-specific ELISA (Direct cAMP ELISA, 900-066, AssayDesign). In some experiments, T cell were incubated with the ERK1/2 specific inhibitor (5 µM) (FR180204, Calbiochem, Billerica, USA) or the PDE4-specific inhibitor rolipram (5µM) (Cayman Chemicals, Ann Harbor, USA), respectively, 1 h prior to IFN-α treatment.
NK cell cytotoxicity assay
Human NK cells were separated using the CD56 + CD16 + NK cell isolation kit (Miltenyi Biotec) resulting in a purity of NK cells between 90-95% (Supplemental Fig. S1 ). Teff and Treg were cultured for 2 hours at 37 °C with or without 10 4 U/ml IFN-α in the presence of 0.5 µg/ml anti-human CD3 (clone OKT-3) and 1 µg/ml anti-human CD28 (BD Pharmingen).
After washing, Teff or Treg were cocultured with isolated NK cells (T cell/NK cell ratio: 2:1) for 4 hours. Subsequently, equal numbers of CFSE (1 µM)-labeled K562 tumor cells (16) and CFSE (0.1 µM)-labeled PBMC (from the NK cell donor) were added (NK/K562 ratio 10:1) to the cultured cells for further 4 hours at 37 °C. Afterwards cells were subjected to flow cytometry (BD FACSCalibur), data analyzed with Summit v4.0 (Dako, Glostrup, Denmark) and killing efficiency determined as the ratio of propidium iodide negative CFSE low control cells (syngeneic PBMC) to CFSE high K562 target cells normalized to background cell death. 
DNA isolation and methylation analysis using bisulfite pyrosequencing
Genomic DNA was isolated from 5-6 x 10 5 T cells. Male donors were used in order to avoid possible artefacts due to random x chromosome inactivation in females. Bisulfite treatment of genomic DNA was performed using the EpiTect Bisulfite Kit (Qiagen, Hilden, Germany).
The methylation status of the FOXP3 TSDR was analyzed by bisulfite pyrosequencing which was performed on a PSQ™96MA Pyrosequencing System (Biotage, Uppsala, Sweden) with the PyroGold SQA reagent kit (Biotage) (17) . PCR and sequencing primers for bisulfite pyrosequencing were designed using the Pyrosequencing Assay Design Software (Biotage) to Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Results
IFN-α abrogates suppressive activity of human CD4 + CD25 high Foxp3 + Treg.
To determine whether IFN-α influences the suppressive activity of human Treg, suppressor assays with cocultures of human CD4 + CD25 -Teff and Treg were set up in the presence of irradiated costimulatory PBMC with or without IFN-α. In this setting, Treg inhibited Teff proliferation up to 88%, dependent on the Treg/Teff ratio ( Fig. 1A, B ). Addition of IFN-α caused a considerable loss in Treg-mediated suppression independent of the Treg/Teff ratios ( Fig. 1A, B ).
In mice, IFN-α modulates the suppressive activity of Treg by affecting the function of antigen-presenting cells (APC) (18) . We therefore compared the effect of IFN-α on human Treg function in the presence and absence of APC (after stimulation with anti-CD3/anti-CD28 mAb). However, in contrast to the murine system, IFN-α abrogated the suppressive function of human Treg both in presence ( Fig. 1A, B ) and absence of APC ( Fig. 1 C) , demonstrating APC independency of the IFN-α-mediated Treg inactivation.
Treg promote tolerance to tumors in mouse models and Treg infiltration in human tumors is associated with worse clinical outcomes (19, 20) . Previously, it was demonstrated that preactivated Treg efficiently suppress the cytotoxic activity of NK cells against tumor cells (21) ( Fig. 2 ). We confirmed these results using a CFSE-based system of NK-mediated cytotoxicity against K562 tumor cells. Here, activated Treg were capable abrogating tumor cell lysis by NK cells (Fig. 2 
IFN-α reduces expression of IFNAR-2 on Treg.
Analysis of IFN receptor chain-2 (IFNAR-2) expression revealed that Treg express slightly higher levels of the receptor compared to Teff, ( 
IFN-α does not affect the Treg differentiation program.
It has been previously suggested that plasmacytoid DC impair the regulatory function of Treg As previously reported, IL-10 contributes to the regulatory activity of Treg (10) and its production is increased in CD4 + T cells after IFN-α treatment (25) . IFN-α neither affected IL-10 nor IFN-γ production of Treg (Fig. 4A ). In Treg/Teff cocultures both IFN-γ and IL-10 levels were slightly increased by IFN-α reflecting reduced Treg activity (Fig. 4A ), whereas no alterations in IL-2 and TGF-β amounts were observed (data not shown).
It is widely accepted that the suppressive function of Treg is linked to their anergic state, associated with low IL-2 production in vitro (9, 10) . However, IFN-α did not induce Treg proliferation as assessed by [ 3 H] thymidine incorporation (Fig. 1A, B ) and by flow cytometry of Treg in suppressor assays (data not shown). Thus, abrogation of Treg suppressive activity by IFN-α does not involve reversion of Treg anergy.
Compelling evidence suggests that the transcription factor Foxp3 acts as a master switch governing the development and function of Treg (9, 10) . Recently, an evolutionary conserved CpG-rich element within the FOXP3 locus was found to be demethylated in Treg (26) . This Treg-specific demethylated region (TSDR) was associated with transcriptional activity and a stable imprinted phenotype of Treg (26) . We therefore additionally analyzed methylation of the TSDR in Treg in response to IFN-α treatment. Teff with high methylation state of the TSDR served as controls (Fig. 4B ). However, bisulfite pyrosequencing of the TSDR revealed Fig. S3 ).
IFN-α induces cAMP deprivation in Treg
As reported recently, up-regulation of endogenous cAMP is required for the suppressor function of murine and human Treg (27) (28) (29) . Consistent with previous reports, assessment of cytosolic cAMP concentrations revealed that Teff produced substantially lower amounts of cytosolic cAMP compared to Treg (Fig. 5A) (27) . IFN-α mediated functional impairment of human Treg was associated with significantly repressed cAMP up-regulation in activated Treg, corroborating the previously identified cAMP dependency of Treg suppressive function ( Fig. 5A ).
Intracellular cAMP levels can be regulated by alterations in the rate of synthesis by adenylate cyclases, degradation by phosphodiesterases (PDEs), or excretion. Human T cells predominantly express the PDE isoforms PDE4B and PDE4D (30) . Blocking PDE activity by the PDE inhibitor IBMX or by the PDE4-specific inhibitor rolipram, respectively, abrogated IFN-α-induced cAMP deprivation and restored the regulatory activity signifying a role of cAMP degradation in IFN-α-mediated Treg inhibition (Fig. 5B, C) . Furthermore, specific inhibition of PDE4 activity in IFN-α-treated Treg resulted in recovery of cAMP levels, confirming PDE4-mediated cAMP degradation as key mechanism in IFN-α-mediated Treg inactivation (Fig. 5D ).
PDE4 isoforms are functionally regulated by the ERK2 MAP kinase and activation of the MEK/ERK-pathway in turn belongs to the prominent actions of IFN-α in human CD4 + T cells (22, 31) . We therefore additionally examined whether IFN-α-induced cAMP deprivation in on July 22, 2017. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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IFN-α negatively regulates T cell-receptor signaling in Treg.
Since Treg up-regulate their cAMP content in response to TCR engagement (27) (28) (29) and cAMP has been shown to participate in regulation of TCR-mediated signaling (32, 33) , we analyzed the impact of IFN-α on Src tyrosine kinase p56lck-mediated ξ-associated protein-70 (ZAP-70) phosphorylation at the Tyr 319 residue as a direct TCR-related downstream signaling event. Importantly, pre-incubation of Treg with IFN-α resulted in decreased ZAP-70 activation in response to TCR-stimulation ( Fig. 6 ), revealing modulation of TCR-signaling in human Treg by IFN-α. However, reduction of the cAMP level in Treg by an adenylate cyclase inhibitor (MDL-12) did not affect ZAP-70 phosphorylation, suggesting that the IFNα-mediated modulation of TCR-mediated signaling in Treg may not be directly linked to the cAMP level (Supplemental Fig. S4) (15) .
IFN-α inhibits Treg-mediated protection from GvHD.
To investigate the effect of IFN-α-treatment on Treg suppressive activity in vivo, we resorted to a previously established xenogeneic graft versus host disease (GvHD) model induced by human T cells in immunodeficient mice that is applicable for the functional analysis of human Treg (15, 34) . Upon intraperitoneal engraftment with human PBMC, newborn Rag2 -/γc -/mice developed lethal GvHD as assessed by loss of body weight (Fig. 7A ) and death (Fig. 7B) within 2 months (Fig. 7B ). In this model, pre-incubation of Treg with IFN-α abrogated their ability to protect from disease onset as compared to untreated Treg (Fig. 7A, B) , without affecting their viability (Fig. 7C) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 22, 2013; DOI: 10.1158/0008-5472. activity in vivo. Human Treg survived only for limited time in vivo, regardless of their pretreatment with IFN-α ( Fig. 7C, right panel) . However, in agreement with previous reports demonstrating that suppression by Treg is confined to the very early phase of GvHD (35, 36) , limited survival of human Treg in vivo did not affect their suppressive activity in GvHD (Fig.   7) . As compared to Treg-injected animals, the xenoreactive population of human effector T cells in IFN-α-Treg treated mice expanded over time and ultimately induced GvHD (Fig. 7C 
Discussion
IFN-α exhibits significant effects in promoting tumorgenicity through activation of immune cells and repression of tumor growth. Herein, we show that IFN-α significantly inactivates the suppressive function of human Treg and thereby releases CD4 + T cells and NK cells from
Treg-mediated suppression. Thus, abrogation of Treg activity by IFN-α adds a novel and conceivable explanation for the immune promoting effect of IFN-α in malignancies (3) (4) (5) including frequently observed autoimmune symptoms upon continuous therapeutic application (6, 7) . In line with this assertion, IFN-α-treatment has been previously observed to reduce Treg numbers in melanoma or renal cell carcinoma patients (37,38) whereas, conversely, declining IFN-α levels and impaired IFN-α signaling in cancer patients seem to be correlated with an increase in the number of Treg and a higher risk of cancer progression (39) (40) (41) . Recent reports on improved immune responses upon co-administration of IFN-α with peptide vaccines in renal (42) , pancreatic (43) and colorectal cancer (44) represent additional evidence.
Numerous investigations have firmly established a key role of cAMP in the suppressive function of Treg (27) (28) (29) (30) (45) (46) (47) . Importantly, within the CD4 + T cell population, Treg exclusively accumulate cAMP. By interfering with the function of cAMP-producing adenylate cyclases (ACs) or cAMP-degrading phosphodiesterases (PDEs) both the suppressive activity and functional state of Treg can be selectively manipulated (15, 27, 29) . It is currently not clear whether differential cAMP up-regulation in human Treg results from differential enzyme endowment or activity, however, it is at least known that human T cells predominantly express the short isoforms PDE4B and PDE4D, which are functionally regulated by ERK2 MAP kinase, and that engagement of the TCR leads to recruitment of a beta-arrestin/phosphodiesterase 4 (PDE4) complex to lipid rafts that serves to degrade the local, TCR-induced production of cAMP (30, 31, 48) . Activation of the MEK/ERK-pathway on July 22, 2017. © 2013 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on July 22, 2013; DOI: 10.1158/0008-5472. again belongs to the prominent actions of IFN-α in human CD4 + T cells (22) . In our study, both blockade of the MAK kinase ERK1/2-regulated pathway and specific inhibition of PDE4 activity completely restored the suppressor activity and accumulation of cAMP in IFN-αtreated Treg. Thus, we show here that IFN-α turns down the cAMP level in Treg by stimulation of the MEK/ERK-pathway (22) leading to ERK-mediated PDE4 activation. This observation is in line with the previous finding that both, ERK inhibition and blockade of cAMP degradation by PDE inhibitors enhances the Treg suppressive function (29, 49) .
IFN-α signals primarily through the JAK/STAT pathway (22) . Comparing IFN-α-mediated STAT signaling in Treg and Teff, we observed similar activation of STAT3 and STAT5 but significantly lower IFN-α-induced STAT1 activation in Treg. The reason for altered STAT1 phosphorylation in Treg is unclear, however, may be consistent with a study reporting that cAMP differentially reduces STAT1 activation in T cells (23) .
In T cells, the IFN-α receptor not only recruits the JAK-STAT pathway, but additionally associates with signaling molecules of the T cell receptor (TCR) signalosome curtailing their availability in TCR signal transduction (50) . Investigating ZAP-70 phosphorylation in place of TCR signaling in Treg, we observed partly decreased ZAP-70 phosphorylation in response to TCR stimulation in presence of IFN-α. However, decreased ZAP-70 phosphorylation did not seem to be directly related to the cAMP level since pharmacological repression of the second messenger by adenylate cyclase blockade did not lead to an altered ZAP-70 activity.
It is widely accepted that the suppressive function of Treg is linked to their anergic state, expression of Treg-function associated surface molecules and production of immunosuppressive cytokines like IL-10 (9,10). Our study revealed that IFN-α did not affect the anergic state, the cytokine profile or expression of surface molecules of human Treg. In addition, the methylation state of the TSDR within the 
